Lowest Price Guaranteed
Pages
607
Last Updated
February 2026
View Count
27987
In most of the cases, hit generation constitutes the majority of the R&D expenditure, leading to around 40% - 50% of the total cost, thus it is expected to hold the majority of the share of the antibody discovery services market.
-- President, US-based small sized company
The global antibody discovery market, valued at $2.0 billion in 2025, is projected to reach $2.2 billion in 2026 and $6.3 billion by 2035, representing a CAGR of 12.3% during the forecast period 2026 to 2035. This market includes the opportunity for antibody discovery service and technologies / platform providers.
The new research study consists of industry trends, detailed market analysis, competitive landscape, partnership and funding activity trends, and market impact analysis. The report also includes antibody discovery services and platforms market forecast and opportunity analysis.
 |
To learn more about this report, request a free sample copy
Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins that are synthesized by B-lymphocytes and circulate within the bloodstream and lymphatic system, playing a pivotal role in the identification and neutralization of foreign substances. Antibodies recognize specific structures on pathogens called antigens, bind to them, and initiate a series of immune responses, subsequently promoting their removal through phagocytosis.
Given the ability of antibodies to target specific proteins, they are considered as highly important biologics that are being used for the treatment of various diseases, including cancer and autoimmune disorders. In fact, apart from cancers, antibody-based therapies have also been used to treat a variety of other diseases, including chronic clinical conditions (such as asthma and rheumatoid arthritis) and multiple rare disease indications.
 |
 |
 |
Over time, advances in antibody research and discovery techniques have enabled the development of a number of versatile antibody types, such as monoclonal antibodies, bispecific antibodies, ADCs, antibody fragments and others. Such products have been designed to offer therapeutic benefits by interacting with proteins / other biological targets in unique ways and thus, offering multiple innovative and viable treatment options.
Statistically, antibody development programs have outperformed, in terms of rate of approval, the other new chemical entities (NCEs). In fact, the chances of antibodies (at IND filling stage) getting approved were observed to be close to 14%; the same figure is 7.6% for other NCEs.
 |
 |
 |
The significant potential of antibodies, particularly monoclonal antibodies, as therapeutic agents have prompted the pharmaceutical developers to undertake several initiatives for their research and development. This can be supported by the fact that, the FDA approved 10 monoclonal antibodies, accounting for around 20% of all new drug approvals in 2024 alone.
Despite the multiple approvals, the discovery of monoclonal antibodies is poised with several challenges, across different stages of design, production, and clinical application. Therefore, antibody developers are opting to outsource discovery services to third-party service providers or license specialized platforms and technologies available with platform providers. However, it is imperative to state that the conventional technologies have their own unique sets of advantages and are gradually becoming obsolete. This has urged the technology / platform providers to develop multiple novel and advanced platforms / technologies in order to remain competitive in this field.
 |
 |
 |
This field holds immense potential for future breakthroughs, wherein advances in artificial intelligence and machine learning are likely to play a pivotal role, enabling the prediction of antibody-antigen interactions and enhancing the efficiency of lead identification. Driven by these advancements, the antibody discovery market is anticipated to evolve over the next several years, benefiting a variety of stakeholders who have steadily promoted innovation in this domain.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in providing services or platforms for the discovery of antibodies, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Forecast Period | Till 2035 | |
| Market Size in 2026 | $ 2.2 Billion | |
| Market Size in 2035 | $ 6.3 Billion | |
| CAGR (till 2035) | CAGR of 12.3% | |
| Antibody Discovery Step |
|
|
| Antibody Discovery Method |
|
|
| Nature of Antibody |
|
|
| Therapeutic Area |
|
|
| Type of Antibody |
|
|
| End-user |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 10% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this market report was to estimate the current antibody discovery services and technologies / platforms market size, opportunity and the future growth potential over the forecast period. Based on multiple relevant parameters, adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035.
The market report also features the likely distribution of the current and forecasted opportunity across various segments, such as antibody discovery step (lead optimization, lead selection and hit generation), antibody discovery method (hybridoma-based methods, phage display library-based methods, transgenic animal-based methods, yeast display-based methods, single cell-based methods and other methods), nature of antibody (human antibodies, humanized antibodies, chimeric antibodies and murine antibodies), therapeutic area (oncological disorders, immunological disorders, infectious diseases, cardiovascular disorders, neurological disorders and other disorders), type of antibody (monoclonal antibodies, bispecific antibodies, antibody drug conjugates, immunoconjugates and other antibodies), type of end-use (in-house players and contract research organizations), and geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).
In order to account for future uncertainties and to add robustness to our model, we have provided three antibody discovery market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the industry stakeholders (arranged in decreasing order of seniority level):
Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
The overall market has been segregated across antibody discovery services and platforms. Detailed insights related to these have been presented in the sections below.
Based on the antibody discovery step, the services segment of antibody discovery market is distributed across lead optimization, lead selection and hit generation. Currently, the lead optimization sub-segment occupies the majority (61%) of the share in the overall market.
This can be attributed to the fact that lead optimization ensures high quality antibody candidates in terms of affinity, stability, and specificity, thereby increasing their likelihood of clinical success. This process is integral to minimize off-target effects and optimize pharmacokinetics, which is crucial for the development of safe and effective therapeutics.
Based on the discovery method, the services segment of antibody discovery market is segmented into hybridoma-based methods, phage display library-based methods, transgenic animal-based methods, yeast display-based methods, single cell-based methods and other methods.
Presently, the market is dominated by hybridoma-based methods (35%). This can be attributed to the popularity of hybridoma-based methods for the discovery of antibodies, owing to its efficiency and low complexity. It is worth highlighting that hybridoma-based methods have been pivotal in developing therapeutic monoclonal antibodies used in treatment of diseases, including cancer, autoimmune disorders, and infections.
Interestingly, since its discovery in 1975 by Kohler and Milstein, this method has been used to develop a number of successful USFDA-approved antibodies. Notable examples of antibodies developed using this method include adalimumab (for autoimmune diseases like rheumatoid arthritis), Opdivo (for squamous cell carcinoma) and Tecentriq (for adjuvant non-small cell lung cancer).
Based on the nature of antibody, the services segment of antibody discovery market is segmented into human antibodies, humanized antibodies, chimeric antibodies and murine antibodies. The human antibodies sub-segment occupies the highest share (53%) in the current global services market.
This can be attributed to several benefits associated with human antibodies, including reduced immunogenicity and the increased serum half-life of the monoclonal antibodies in humans. It is worth mentioning that, in 2024, over 15 fully human monoclonal antibodies have been approved across various geographies.
The global market value for services segment of antibody discovery market, based on different therapeutic areas, is segmented into oncological disorders, immunological disorders, infectious diseases, cardiovascular disorders, neurological disorders and other disorders. Currently, the market is dominated by oncological disorders sub-segment (48%). This can be attributed to the fact that incidence of oncological disorders has been on the rise globally, necessitating the development and production of effective treatments, including antibody-based therapeutics.
Various novel antibody-based therapies have shown promising results in treating oncological disorders. However, it is important to note that the growth rate associated with cardiovascular disorders is expected to be on the rise in the coming years. This can be attributed to the rise in demand for more targeted treatments, along with the promising therapeutic potential for addressing complex cardiovascular conditions.
Based on the type of antibody, the global services segment of antibody discovery market is segmented into monoclonal antibodies, bispecific antibodies and immunoconjugates. Presently, the market is dominated by monoclonal antibodies (60%) and the trend is unlikely to change in the future as well. This can be attributed to the fact that monoclonal antibodies offer high specificity, consistency, and reproducibility, thereby making them ideal for targeted therapies. In addition, mAbs have proven to be highly effective in treating a range of diseases, including cancer, autoimmune disorders, and infectious diseases.
Similarly, based on the type of antibody, the global technologies / platforms market is segmented into monoclonal antibodies, bispecific antibodies, antibody drug conjugates and other antibodies. The monoclonal antibodies segment (51%) occupies the highest market share, and this trend is unlikely to change in the foreseen future as well. Notably, 10 monoclonal antibodies have been approved by FDA in the year 2024.
The technologies / platforms market for bispecific antibodies is expected to grow at a higher CAGR of 9.51% during the period 2025-2035. This can be attributed to the various benefits associated with bispecific antibodies compared to the conventional forms of antibodies, such as higher binding affinity, improved selectivity and the ability to interact with multiple targets.
The global technologies / platforms market segment of antibody discovery market is segmented across different end-users, namely in-house players and contract research organizations. In-house players’ sub-segment (98%) occupies the highest market share. This can be attributed to the fact that in-house players mostly have dedicated teams, access to extensive in-house resources, and control over intellectual property, which enables them to streamline the discovery process and maintain competitive advantages.
This segment highlights the distribution of global services market size across geographical regions, such as North America (US and Canada), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea and Australia), Middle East and North Africa (Egypt, Israel, Saudi Arabia and Middle East and North Africa), and Latin America (Brazil, Argentina, Mexico and Rest of Latin America).
According to our projections, North America is likely to capture the majority (50%) share of the market, owing to the presence of big pharma players, well-established regulatory framework, and various technological advancements in this region. On the contrary, Asia-Pacific is poised for the healthy growth rate (with a CAGR of 13.3%) during the forecast period.
Similarly, technologies / platforms market is segmented across various geographies, including North America (US and Canada), Europe (UK, Switzerland, Germany, France, and Rest of Europe) and Asia-Pacific (China, Japan, South Korea and Singapore). According to our projections, North America is likely to capture the majority of the overall market share during the period 2025-2035, driven by maximum number of technology licensing / integration deals inked by technology / platform providers headquartered in this region.
Further, the market in Asia-Pacific is anticipated to increase at a faster pace (CAGR of 9.30%) in the foreseen future. This can be attributed to the ongoing efforts of companies for expanding their antibody discovery processes in this region for long-term growth and success.
The “Antibody Discovery Market (6th Edition) - Focus on Services and Platforms: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the players involved in this domain. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biotechnology and pharmaceutical industry. Key takeaways of the market report are briefly discussed below.
Presently, close to 125 service providers are involved in this domain and the current market landscape features the presence of very large, large, mid-sized and small companies. Of these, 43% of the companies are small-sized, indicating significant start-up activity in this industry. Notable examples of these start-ups include (small companies established post-2015, arranged in alphabetical order) Ab Studio, AlivaMab Biologics, Alpha Lifetech, Atlantis Biosciences, Jotbody and Specifica.
Close to 265 technologies / platforms are provided by industry players active in this domain. Of these, the majority (59%) of the technologies / platforms employ library-based method for the discovery of antibodies. This is followed by technologies using single cell method (33%).
Notable examples of technologies that employ library-based method include (technologies provided by mid-sized companies, arranged in alphabetical order of the technology provider) Dynamic Precision Library Platform and NEObody (provided by Adagene), Adimab technology (provided by Adimab), SHM (provided by AnaptysBio) and n-CoDeR antibody library (provided by BioInvent).
In addition, the majority (68%) of the technologies / platforms have the capability to discover monoclonal antibodies. Notable examples of technologies intended for the discovery of monoclonal antibodies include (arranged in alphabetical order of the provider) Imbalanced bispecific antibody platform and Serial Internalizing Antibody platform (provided by AbStudio), RabMab (provided by Abcam), and AbCellera technology (provided by AbCellera).
Recent advancements in biotechnology, increasing demand for targeted therapies, ever-increasing prevalence of chronic diseases, increase in R&D expenditure in pharma and growing trend for outsourcing Ab discovery operations are some of the key factors thar are driving the market growth.
In addition, the significant interest from investors has led to a strong spur in investment activity, further contributing to the market’s growth. Notably, a cumulative amount of over USD 36 billion has been raised in this market since 2021. It is worth noting that majority of the funds have been raised through debt financing. In terms of the funding amount raised, Thermo Fisher Scientific raised the maximum funding amount (USD 6,209 million) through debt financing.
Several stakeholders have been forging alliances with other players (industry / non-industry) active in this industry for different purposes, including product / technology licensing, research and development, and technology utilization. It is worth highlighting that, since 2021, more than 270 strategic partnerships have been inked by the technology providers in this domain. It is important to mention that 30% of the partnership agreements inked in 2024 were research and development agreements, followed by product / technology licensing agreements.
Recent examples of product / technology licensing agreements include (in reverse chronological order) the agreements signed by Harbour BioMed with Windward Bio (January 2025), Hummingbird Bioscience and Immunome (January 2025), Antibody Solutions and Leveragen (December 2024), and Harbour BioMed and Kodiak Sciences (December 2024). With more companies licensing their technologies for evaluation, the market is expected to witness favorable market growth during the forecast period.
Over the past few years, there has been a steady increase in the establishment of companies offering various technologies / platforms for the discovery of antibodies, primarily in North America. It is worth noting that this region currently holds the highest market share (60%) of the technologies / platforms market.
Further, the market in Asia-Pacific is anticipated to increase at a faster pace (CAGR of 9.30%) in the foreseen future. A few examples of mid-sized companies based in North America with AI-enabled technology / platform, include Absci, Alloy Therapeutics, BigHat Biosciences, Creative Biolabs, GV20 Therapeutics, HiFiBio Therapeutics, ImmunoPrecise Antibodies and OmniAb.
Examples of key companies in this market (arranged in alphabetical order, which have also been profiled in this market report; the complete list of companies is available in the full report) include Ablexis, Abwiz Bio, Abzena, Aragen Life Sciences, BIOTEM, ChemPartner, Creative Biolabs, DetaiBio, FairJourney Biologics, Fusion Antibodies, Genmab, Harbour BioMed, Immunome, ImmunoPrecise Antibodies, Integral Molecular, Isogenica, ProteoGenix, Syd Labs, Viva Biotech and WuXi Biologics.
This market report includes an easily searchable excel database of all the antibody discovery services and platforms companies worldwide.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market research report includes:
Several recent developments have taken place in this field. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our genome editing market analysis.